genome-targeted therapy eligibility response

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

by A. Haslam, M.S. Kim, V. Prasad

Apr 20^th 2021
7 mins
ESMO; Volume 32, Issue 7, p926-932, July 2021

Share This Article

Summary

Recent studies have been conducted to update the estimates of eligibility and response rates to genome-targeted therapies among US cancer patients, reflecting data up to 2020.
The number of FDA-approved drugs targeting genetic indications has increased significantly since prior assessments.
Eligibility for genome-targeted therapies has risen from 5.13% in 2006 to 13.60% in 2020.
Response rates to these therapies have increased from 2.73% in 2006 to 7.04% in 2020.
The most significant growth in eligibility occurred after 2018, while response rate growth was more pronounced before 2018.

Precision oncology relies upon genomic sequencing of a patient’s tumor to determine optimal treatment. Precision therapies typically target genetic aberrations within cancer, and this approach has widespread enthusiasm driven by high response rates. Often, genomically-targeted drugs gain Food and Drug Administration (FDA) approval in single-arm trials that lack a comparator group. As such, response rates, which measure the percentage of patients who have tumor shrinkage beyond the RECIST 1.1 cut-off of 30%, are often used as a study endpoint.

Prior studies have evaluated the percentage of US cancer patients with advanced or metastatic cancer who are eligible for and respond to this class of medications. Specifically, genome-targeted therapy was found to apply to 8.3% of US cancer patients as of 2018, and 4.9% might experience a partial or complete response. However, since that publication, the number of FDA approvals for drugs targeting genetic indications has grown rapidly. We therefore sought to update the estimates of both eligibility for and response to genome-targeted and genome-informed therapies for drugs that have been FDA-approved to reflect estimates as of 2020.

Click for Source Download PDF version

genome-targeted therapy, eligibility, response

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Share This Article

Related Topics

Meet Our Innovation Partners

You May Also Like

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN